BioSpace News Archive

Know Labs, Inc. today announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on March 6-9, 2024.

Specialty cancer diagnostics company Precipio, Inc. announces that continued revenue growth generated cash levels that bring the company closer to breakeven.

Nalu Medical, Inc. presented interim data from the landmark COMFORT randomized controlled trial at the 2024 North American Neuromodulation Society Annual Meeting in Las Vegas, Nevada.

Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF administration in the first participant, an individual with a decade-plus history of profound hearing loss.

Florida Cancer Specialists & Research Institute, LLC Senior Vice President & Data Officer Trevor Heritage, PhD will share learnings gained from the statewide practice’s development of an innovative propriety precision oncology platform at the Precision Medicine World Conference being held this month in Santa Clara, California.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of a new sub-brand, RenBiologics™, to represent the company’s antibody discovery business division.

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, has scheduled the release of its 2023 fourth quarter and full year financial results for Monday, February 5, 2024 before the market opens.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2023 financial results and guidance will be released on Tuesday, February 6, 2024 after the market closes.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Precision Optics Corporation, Inc. (NASDAQ: POCI) today announced that Dr. Joe Forkey, Chief Executive Officer, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference, taking place virtually on February 1, 2024.